Considering the crucial role of antigen presentation function in the efficacy of therapeutic immune checkpoint inhibition, the inclusion of a functional marker (HLA-DR) in a fused indicator could be useful in complementing existing biomarkers, such as PD-L1 expression and tumor mutational burden, in guiding immunotherapy. This evidence concerns the gene CD274 and neoplasm.